Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 550.5 DKK 3.19% Market Closed
Market Cap: 39.1B DKK

EV/EBITDA
Enterprise Value to EBITDA

-25
Current
-17.5
Median
4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-25
=
Enterprise Value
31B DKK
/
EBITDA
-1.2B DKK
Market Cap EV/EBITDA
DK
Zealand Pharma A/S
CSE:ZEAL
38.9B DKK -25
FR
Pharnext SCA
OTC:PNEXF
6T USD -212 079.3
US
Abbvie Inc
NYSE:ABBV
361.9B USD 16.7
US
Amgen Inc
NASDAQ:AMGN
165.1B USD 16.3
US
Gilead Sciences Inc
NASDAQ:GILD
139.4B USD 11.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.7B USD 26.1
US
Epizyme Inc
F:EPE
94.1B EUR -532.7
AU
CSL Ltd
ASX:CSL
122.4B AUD 17.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
70.3B USD 10.3
US
Seagen Inc
F:SGT
39.3B EUR -60.9
NL
argenx SE
XBRU:ARGX
33B EUR 312.5
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBITDA: 58.7
Negative Multiple: -25
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -212 079.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.3
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11.4
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.1
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.3
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.9 N/A N/A
NL
argenx SE
XBRU:ARGX
312.5
166%
1.9

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-15.9
2-Years Forward
EV/EBITDA
-60.1
3-Years Forward
EV/EBITDA
-62.5